Cellular and Biochemical Mechanisms of the Resistance of Human Cancer Cells to a New Anticancer Ribo‐nucleoside, TAS‐106

por Shimamoto, Yuji, Kazuno, Hiromi, Murakami, Yuko, Azuma, Atsushi, Koizumi, Katsuhisa, Matsuda, Akira, Sasaki, Takuma, Fukushima, Masakazu
Publicado 2002

Antitumor Activity and Pharmacokinetics of TAS‐106, l‐(3‐C‐Ethynyl‐β‐D‐ribo‐pentofuranosyl)cytosine

por Shimamoto, Yuji, Fujioka, Akio, Kazuno, Hiromi, Murakami, Yuko, Ohshimo, Hideyuki, Kato, Toshiyuki, Matsuda, Akira, Sasaki, Takuma, Fukushima, Masakazu
Publicado 2001

Sensitivity of Human Cancer Cells to the New Anticancer Ribo‐nucleoside TAS–106 Is Correlated with Expression of Uridine‐cytidine Kinase 2

por Shimamoto, Yuji, Koizumi, Katsuhisa, Okabe, Hiroyuki, Kazuno, Hiromi, Murakami, Yuko, Nakagawa, Fumio, Matsuda, Akira, Sasaki, Takuma, Fukushima, Masakazu
Publicado 2002

Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2′-deoxy-5-fluorouridine into DNA

por SAKAMOTO, KAZUKI, YOKOGAWA, TATSUSHI, UENO, HIROYUKI, OGUCHI, KEI, KAZUNO, HIROMI, ISHIDA, KEIJI, TANAKA, NOZOMU, OSADA, AKIKO, YAMADA, YUKARI, OKABE, HIROYUKI, MATSUO, KENICHI
Publicado 2015

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models

por TANAKA, NOZOMU, SAKAMOTO, KAZUKI, OKABE, HIROYUKI, FUJIOKA, AKIO, YAMAMURA, KEISUKE, NAKAGAWA, FUMIO, NAGASE, HIDEKI, YOKOGAWA, TATSUSHI, OGUCHI, KEI, ISHIDA, KEIJI, OSADA, AKIKO, KAZUNO, HIROMI, YAMADA, YUKARI, MATSUO, KENICHI
Publicado 2014